Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 4—April 2018
Research

Influenza A(H7N9) Virus Antibody Responses in Survivors 1 Year after Infection, China, 2017

Mai-Juan Ma1, Cheng Liu1, Meng-Na Wu, Teng Zhao, Guo-Lin Wang, Yang Yang, Hong-Jing Gu, Peng-Wei Cui, Yuan-Yuan Pang, Ya-Yun Tan, Hui Hang, Bao Lin, Jiang-Chun Qin, Li-Qun FangComments to Author , Wu-Chun CaoComments to Author , and Li-Ling ChengComments to Author 
Author affiliations: Beijing Institute of Microbiology and Epidemiology, Beijing, China (M.-J. Ma, M.-N. Wu, T. Zhao, G.-L. Wang, H.-J. Gu, L.-Q. Fang, W.-C. Cao); University of Florida, Gainesville, Florida, USA (Y. Yang); Suzhou Municipal Center for Disease Control and Prevention, Suzhou, China (C. Liu, P.-W. Cui, Y.-Y. Pang, Y.-Y. Tan, H. Hang, B. Lin, J.-C. Qin, L.-L. Chen)

Main Article

Table 4

Antibody titers in survivors of influenza A(H7N9) during the acute phase and at 3 follow-up points, China, 2017*

Patient no.
 HI/NI/MN/IgG/IgA titers
Acute phase
 Follow-up visit 1
 Follow-up visit 2
 Follow-up visit 3
1 20/5/5/50/25 10/80/10/1600/50 10/40/10/800/25 10/20/10/800/25
2 20/5/5/50/50 10/10/20/1600/100 10/10/20/400/50 10/5/20/400/50
3 160/20/5/400/200 320/160/160/6400/50 160/160/320/6400/25 40/40/160/1600/25
4 40/320/20/400/25 40/320/20/3200/100 20/40/10/1600/25 5/10/10/800/25
5 5/5/5/100/25 640/5120/640/25600/1600 320/320/320/12800/800 40/80/320/3200/400
6 20/20/5/400/50 320/1280/160/3200/200 160/160/640/800/100 20/40/160/800/100
7 40/40/5/200/200 320/320/160/6400/800 NA NA
8 40/5/5/50/25 320/320/40/1600/400 80/80/40/1600/200 20/20/40/800/100
9 5/5/5/100/25 80/1280/160/51200/400 40/40/160/6400/50 40/40/160/6400/50
10 1280/2560/160/12800/1600 160/2560/160/51200/800 80/320/320/12800/400 40/80/320/3200/200
11 40/10/5/100/100 80/80/80/6400/400 40/20/40/400/200 20/20/80/1600/100
12 40/40/5/800/50 80/5120/40/25600/200 NA NA
13 20/10/5/400/100 160/1280/160/12800/400 80/320/320/3200/200 40/80/160/1600/200
14 5/5/5/50/25 160/160/160/3200/400 40/40/40/800/100 20/20/40/800/100
15 160/5120/160/3200/800 80/5120/160/3200/200 40/80/160/1600/25 20/80/160/1600/25
16 640/5120/160/12800/400 160/640/80/6400/800 80/320/160/3200/400 40/80/160/1600/400
17 20/160/5/100/25 160/320/80/12800/400 80/80/80/1600/400 40/40/80/1600/400
18 80/5/80/100/25 80/1280/80/1600/50 40/80/160/800/25 20/40/160/800/25
19 40/80/10/200/25 320/2560/640/25600/25 40/160/160/1600/25 20/40/160/1600/25
20 40/640/20/800/200 320/5120/640/3200/200 160/160/1280/6400/200 NA
21 NA 160/5120/40/6400/100 40/160/40/1600/25 20/80/40/1600/25
22 20/640/40/25/25 80/1280/40/3200/100 40/320/80/800/25 20/20/40/400/25
23 20/40/5/1600/200 320/5120/160/25600/800 80/160/160/3200/400 80/80/160/1600/400
24 NA 80/640/40/12800/100 40/160/160/3200/50 20/40/40/1600/50
25 NA 40/80/40/3200/50 20/20/40/1600/25 5/10/40/400/25

*HI, hemagglutination inhibition; MN, microneutralization; NA, not available; NI, neuraminidase inhibition.

Main Article

1These authors contributed equally to this article.

Page created: June 22, 2018
Page updated: June 22, 2018
Page reviewed: June 22, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external